Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

Schizophrenia Clinical Trial

Official title:

Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A Inhibitor) in Patients With an Acute Exacerbation of Schizophrenia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05278156
• Other study ID #: 02PDE2019
• Status: Recruiting
• Phase: Phase 2
• Start date: May 19, 2021
• Est. completion date: July 2024

Study information

• Verified date: May 2024
• Source: Celon Pharma SA
• Contact: CROS CRO Sp. z o. o.
• Phone: +48 796 197 603
• Email: info[@]cros-cro.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia after 28 days of administration..

Description:

This is a double-blind, randomized, placebo controlled, parallel group, dose ranging study to explore the efficacy, safety, tolerability and PK of 2 different doses of CPL500036 (phosphodiesterase 10A [PDE10A] inhibitor) in patients with an acute exacerbation of schizophrenia. Approximately 165 patients will be randomized at a 1:1:1 ratio and will be dosed with 20 mg CPL500036, 40 mg CPL500036 or placebo once daily for 28 consecutive days (Day 1 to Day 28). Patients will remain in house for the duration of the Treatment Period. The study will comprise of a Screening Period (that will include a prior Medication Washout Period), a Treatment Period and a Follow-up Period. After discharge from the Clinical Unit, patients will return to the Clinical Unit for 2 once weekly Follow-up Visits. Approximately 30% of the patients (17 patients in each of the 3 treatment groups) will undergo extensive PK sampling during the Treatment Period, and the remaining 70% of the patients will only undergo sparse PK sampling.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 165
• Est. completion date: July 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. The patient has a primary diagnosis of schizophrenia confirmed by clinical interview [SCID-5-CT].

2. Male or female patient aged 18 to 65, inclusive, at Screening.

3. The patient's with exacerbation of psychotic symptoms

4. The patient has a score of 5 or higher in 3 or more items of the following PANSS items at Screening and Baseline

5. The patient has a PANSS Total Score of 80 or higher during Screening and on Baseline

6. The patient of childbearing potential willing to use acceptable forms of contraception.

7. The patient has a score in CGI-S scale of 4 or greater at Screening and on Baseline

8. The patient is able to and agrees to remain off prior antipsychotic medication and all excluded medications as outlined in the protocol for the duration of the Treatment Period.

9. The patient is able to sign informed consent after receiving information about the trial and has the ability and willingness to comply with the requirements and restrictions of the study protocol.

Exclusion Criteria:

1. The patient has a decrease in the PANSS Total Score at Baseline compared with the Total Score at Screening.

2. Patient who recently participated in another interventional clinical study with an Investigational Medicinal Product.

3. The patient has uncontrolled abnormality which may impact the ability of the patient to participate or potentially confound the study results.

4. The patient has a history of severe head injury, traumatic brain injury, myocardial infarction or stroke.

5. The patient has a moderate or severe substance use disorder for alcohol or other substances of abuse except nicotine or caffeine.

6. The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.

7. The patient has a history of or known personality disorder or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.

8. The patient is considered by the Investigator to be at imminent risk of suicide or injury to self or others.

9. The patient has chronic movement disorder that may interfere with the interpretation of study results.

10. The patient has any existing or previous history of cancer or has newly diagnosed diabetes.

11. The patient has long QT syndrome or is under treatment with antiarrhythmic drugs.

12. The patient is considered to be treatment resistant. .

13. The patient has received electroconvulsive therapy.

14. The patient has any laboratory values outside the normal range that are considered by the Investigator to be clinically significant at Screening.

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• CPL500036 - low dose
CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
• CPL500036 - high dose
CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily.
• Placebo
Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.

Locations

Country	Name	City	State
Hungary	Department of Psychiatry and Psychotheraapy of Semmelweis University	Budapest
Hungary	Department of Psychiatry, Mental hygiene and Addictology of Petz Aladár County Teaching Hospital	Gyor
Hungary	Psychiatry Department of Tolna County Balassa Janos Hospital	Szekszárd
Poland	Uniwersytecki Szpital Kliniczny	Bialystok
Poland	Wojewódzki Szpital dla Nerwowo i Psychicznie Chorych	Boleslawiec
Poland	Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej	Choroszcz
Poland	Specjalistyczny Psychiatryczny Zespól Opieki Zdrowotnej	Lódz
Poland	Szpital Neuropsychiatryczny, Samodzielny Publiczny Zaklad Opieki Zdrowotnej	Lublin
Poland	Klinika Psychiatrii Doroslych Uniwersytetu Medycznego w Poznaniu	Poznan
Poland	Wojewódzki Szpital dla Psychicznie i Nerwowo Chorych	Swiecie
Ukraine	Ivano-Frankivsk National Medical University, Department of Psychiatry, Narcology and Medical Psychology	Ivano-Frankivsk
Ukraine	Communal non-commercial enterprise of the Kyiv Regional Council "Regional Psychiatric-Narcological Medical Association", women's department No. 2, men's department No. 10.	Kyiv
Ukraine	Communal non-profit enterprise "Clinical Hospital "PSYCHIATRY"" of the executive body of the Kyiv City Council (Kyiv City State Administration), Center for Primary Psychotic Episode and Modern Treatment Methods.	Kyiv
Ukraine	Communal non- commercial enterprise of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital",	Lviv
Ukraine	Communal non-commercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Psychoneurological Dispensary",	Lviv
Ukraine	Ternopil National Medical University named after I.Y. Gorbachevskiy of the Ministry of Health of Ukraine, Department of Psychiatry, Narcology and Medical Psychology	Ternopil
Ukraine	Vinnytsia National Medical University named after M.I. Pirogov, Department of Psychiatry, Narcology and Psychotherapy with a course of postgraduate education	Vinnytsia

Sponsors (2)

Lead Sponsor	Collaborator
Celon Pharma SA	National Center for Research and Development, Poland

Countries where clinical trial is conducted

Hungary,  Poland,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in PANSS positive subscale at Day 28.	The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.	Day -1, Day 28
Secondary	Change from baseline in PANSS positive subscale at Week 1, 2 and 3	The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.	Day -1, Week 1, 2 and 3
Secondary	Change from baseline in PANSS Total Score at Weeks 1, 2, 3, 4	The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.	Day -1, Week 1, 2, 3 and 4
Secondary	Change from Baseline in PANSS Subscales Using the Marder 5 factor Model at Weeks 1, 2, 3, and 4	The PANSS is a 30-item scale used to measure symptoms of schizophrenia.	Day -1, Week 1, 2, 3 and 4
Secondary	Change from Baseline in PANSS Negative Subscales at Weeks 1, 2, 3 and 4	The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.	Day -1, Week 1, 2, 3 and 4
Secondary	Change from Baseline in PANSS general psychopathology Subscale at Weeks 1, 2, 3 and 4	The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient.Total score is 210 points. The higher PANSS total score, the more severe schizophrenia.	Day -1, Week 1, 2, 3 and 4
Secondary	Percentage of Clinical Responders Based on the PANSS Total Score.	Clinical responder is defined as a = 30% decrease from baseline.	Day -1, Week 1, 2, 3 and 4
Secondary	Change from Baseline in Clinical Global Impression Severity (CGI-S) Score at Weeks 1, 2, 3, and 4	CGI-S scale is a physician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment. It is a 7-point assessment where 1= normal (not at all ill) and 7 = among the most extremely ill patients.	Day -1, Week 1, 2, 3 and 4
Secondary	Clinical Global Impression Scale Improvement (CGI-I) Score at Weeks 1, 2, 3, 4.	CGI-I is a 7 points scale that requires the clinician to assess how much the patient's illness has improved or worsened during treatment. It is a 7-point assessment where 1= Very much improved and 7 = Very much worse	Day -1, Week 1, 2, 3 and 4
Secondary	Change from Baseline in Brief Assessment of Cognition in Schizophrenia (BACS) Score at Weeks 2 and 4.	BACS is specifically designed to measure treatment-related improvements in cognition. The BACS is a cognition assessment battery that assesses 6 domains of cognitive function found to be consistently impaired in schizophrenia: verbal memory, working memory, motor speed, attention, executive functions, and verbal fluency.	Day -1, Week 2 and 4
Secondary	Number of abnormal clinically significant values in vital signs (heart rate, blood pressure, respiratory rate) results.		up to 6 weeks
Secondary	Number of abnormal clinically significant findings in electrocardiogram results.	The following electrocardiogram parameters will be assess: PR interval, QRS interval, RR interval, QT interval and QTc interval.	up to 6 weeks
Secondary	Number of abnormal clinically significant values in laboratory tests (hematologic, clinical chemistry, coagulation and urinalysis) results.		up to 6 weeks
Secondary	Number of abnormal physical, neurological, ophthalmological and dermatological examination findings.		up to 6 weeks
Secondary	Number and intensity of extrapyramidal side effects.	It will be assessed by using Extrapyramidal Symptom Rating Scale (ESRS). This scale is using to assess four types of drug-induced movement disorders (DIMD): Parkinsonism, akathisia, dystonia, and tardive dyskinesia.	up to 6 weeks
Secondary	Number of adverse events.	All adverse events that occurence during study will be assessed.	up to 6 weeks
Secondary	CPL500036 Cmax - Maximum observed concentration		up to 24 hours after administration on Day 7
Secondary	CPL500036 Tmax - Time corresponding to occurrence of Cmax		up to 24 hours after administration on Day 7
Secondary	CPL500036 AUC (0-24h) - Area under the curve from time zero to 24 hours		up to 24 hours after administration on Day 7
Secondary	CPL500036 AUC T1/2 - Apparent terminal elimination half-life		up to 24 hours after administration on Day 7
Secondary	CPL500036 CL/F (Apparent clearance) and Vz/F (apparent volume of distribution during terminal phase)		up to 24 hours after administration on Day 7
Secondary	CPL500036 Cthrough - Concentration immediately prior to dosing		up to 24 hours after administration on Day 7